MicroRNAs (miRNAs) have important roles in the initiation and progression of human cancer, but their role in head and neck cancer development and progression is not well defined. We aimed to determine whether specific miRNAs and their target mRNAs contribute to head and neck cancer pathogenesis and progression. To identify miRNAs associated with head and neck squamous cell carcinomas (HNSCCs), we analyzed HNSCC cell lines, normal head and neck tissues and normal keratinocytes by miRNA profiling; a group of differentially expressed miRNAs was identified, which includes miR-125b. Decreased expression of miR-125b is known to occur in epithelial cancers and many target mRNAs for this miR have been reported. We found decreased expression of miR-125b-1 and hypermethylation of its promoter in HNSCC compared with its non-malignant counterpart. The TACSTD2 (also known as TROP2) gene was identified and validated as a direct target of miR-125b-1. Abnormal expression of TACSTD2 cell-surface glycoprotein has been reported in most epithelial tumors, and the overexpressions of this mRNA and protein product has been considered a useful tumor marker. We report that miR-125b-1 causes mitogen-activated protein kinase pathway dysfunction through regulation of TACSTD2 expression. Thus, loss of miR-125b-1 may have a key role in the pathogenesis and progression of squamous cell carcinomas of head and neck and possibly of other tumors.
INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common neoplasm worldwide, and includes tumors of the oral cavity, larynx and pharynx. 1 Although diagnosis and treatment of HNSCC have improved, the survival rate has not improved substantially in the past 40 years. 2, 3 In this study, we focus on the relationship between HNSCC and microRNA (miRNA) dysregulation.
miRNAs are 19-24 nucleotide noncoding RNAs that regulate the translation and degradation of target mRNAs, 4, 5 and a large fraction of protein-coding genes are under the control of miRNAs. miRNAs have a fundamental role in the regulation of important cellular functions, such as proliferation, apoptosis, death, stress response, differentiation and development, and dysregulation of miRNA is associated with a variety of disorders, in particular cancers, including HNSCC. [6] [7] [8] Recent studies have demonstrated that miR-125b is dysregulated in multiple types of cancer, including breast, 9 oral, 10 bladder 11 and anaplastic thyroid carcinomas, 12 suggesting that miR-125b could have a role in tumor development. miR-125b-1 and miR-125b-2 originated from independent precursors located on different chromosome loci, but their mature sequences and targets are identical. In this study, we found that expression of miR-125b-1 is suppressed in HNSCC cell lines, in association with TACSTD2 overexpression. TACSTD2 is a 36-kDa cell-surface glycoprotein overexpressed in a variety of late stage epithelial carcinomas with low-to-no expression in normal tissues; [13] [14] [15] [16] [17] it is overexpressed in a variety of human cancers, both metastatic and invasive tumors. Analysis of tumor tissues from cancer patients revealed association of increased TACSTD2 expression with poor prognosis and higher frequency of metastasis. 13, 14, 16, 17 In this study, the TACSTD2 gene was identified as a direct and functional target of miR-125b-1 in squamous cell carcinogenesis. Upmodulation of miR-125b-1 expression inhibited cell invasion, colony formation and anchorage-independent growth of HNSCC cells. We further showed that miR-125b-1 may regulate the extracellular signal-regulated kinase (ERK)-MAPK (mitogenactivated protein kinase) signaling pathway in HNSCC. Thus, our findings reveal novel roles of miR-125b-1 in the pathogenesis and progression of epithelial tumors.
RESULTS

miRNA expression signature differentiates HNSCCs from nonneoplastic head and neck cells or tissue
We analyzed the miRNA expression profiles of seven human HNSCC-derived cell lines, three normal primary oral keratinocyte cells and head and neck tissues from two healthy subjects, using a miRNA microarray platform for genome-wide assessment of expression levels of human miRNAs. 18, 19 Marked differences in expression were observed in 292 human miRNAs of HNSCCs vs non-cancer tissues or cell lines. Using twofold expression difference as a cutoff level, we identified 72 upregulated and 43 downregulated miRNAs. Expression of 20 miRNAs was altered more than fourfold in HNSCC samples (fold change: 44, false discovery rate: o0.05). Among these, miR-125b was the most significantly downregulated miRNA ( À 100-fold), (Table 1, Figure 1a ) and its downregulation was validated by quantitative real-time PCR (qPCR; Figure 1b ). miR-125b-1 is hypermethylated in SCC To examine mechanisms of downregulation of miR-125b expression in HNSCC, we assessed the deletion and methylation status of the locus. We selected 2000 bps of sequence upstream of miR-125b-1 and miR-125b-2 (Figure 2a ) for examination. Two CpG-rich regions upstream of miR-125b-1 and one CpG-rich region upstream of miR-125b-2 were found by using the MethPrimer online tool (http://www.urogene.org/methprimer/). CpG island region 1 upstream of miR-125b-1 was found to be hypermethylated in all HNSCC cells, while non-cancer cells showed absence of methylation. The CpG island region upstream of miR-125b-2 was not methylated in the HNSCC cells (Figure 2b upper). Expression of the hypermethylated miR-125b was restored after treatment with the demethylating agent, 5-aza-2 0 -deoxycytidine (5-aza-CdR), for 5 days (Figure 2c ). To assess the correlation between DNA methylation status of miR-125b-1, 2 and expression of the two loci, we performed real-time PCR analysis of precursor miR-125b-1, 2. We found that the gene expression in hypermethylated miR-125b-1 locus, but not miR-125b-2, was repressed in all HNSCC cells (Figure 2d ). By using real-time or end-point PCR analysis, we searched for deletion of the miR-125b-1, 2. In this result, we found some differences of copy number. However, there is no significant difference between normal keratinocytes and HNSCC cells, and we did not observe any loss at the genomic region of either of the miR-125b-1, 2 loci (Figures 2b and e lower  panel) . These results suggest that the loss of expression of miR-125b-1 was caused by promoter methylation and matured miR-125b expression reflects it.
TACSTD2 is a target of SCC-deregulated miR-125b-1 by miRNA target prediction Identification of miRNA-regulated gene targets is a necessary step to understand miRNA functions. We searched for additional miR-125b-1 targets using computer-aided miRNA target prediction programs, MicroCosm Targets (http://www.ebi.ac.uk/enrightsrv/microcosm/htdocs/targets/v5/), TargetScan (http://www. targetscan.org/), PicTar (http://pictar.mdc-berlin.de/), miRBase targets and miRanda (microrna.org and miRbase), and 41000 candidate downstream targets of miR-125b were identified, including many putative miR-125b-1 target genes that might have a role in cell invasion, such as EPHA2, RAB13, MAP3K11, CDKN2A and TACSTD2. We performed qPCR analysis in HNSCC cells compared with normal samples. Among these candidate genes, we found that TACSTD2 mRNA and protein levels were overexpressed in HNSCCs and showed an inverse correlation with miR-125b-1 expression (Figures 3a and b) . TACSTD2 was selected as a promising candidate of the target. The TACSTD2 gene product is a cell-surface glycoprotein belonging to the TACSTD gene family and is highly overexpressed by a variety of epithelial carcinomas with low or no expression in normal tissues. [13] [14] [15] [16] [17] We found that overexpression of miR-125b-1 using precursor miRNA oligo and miRNA-expressing lentivirus in both SCC9 and FaDu cells reduced the mRNA level of TACSTD2 450% (*Po0.05). miR-125b-1 regulates TACSTD2 and MAPK pathway H Nakanishi et al Furthermore, transfection of a miR-125b inhibitor antisense miRNA into SCC9 FaDu, hOMK102 and hOMK107 cells led to markedly increased expression of TACSTD2 (Figure 4 ). MiRanda analysis indicated that TACSTD2 contains one miR-125b-binding site in its 3' untranslated region (UTR; Figure 5a ), a site highly conserved across primates species (chimpanzee, rhesus macaque and human) but not rodents (Figure 5b ). Therefore, we constructed vectors containing wild type or mutant 3 0 -UTR of human TACSTD2 fused downstream of the firefly luciferase gene. The wild-type or mutant vector was co-transfected into HEK-293T cells with miR-125b-1 expression construct or vector control. The transfection efficacy was normalized by co-transfection with renilla reporter vector. As shown in Figure 5c upper part, miR-125b-1 expression led to significantly decreased relative luciferase activity of wild-type TACSTD2 3 0 -UTR (450%), whereas reduction of luciferase activity with mutant TACSTD2 3 0 -UTR was not detected.
We also performed luciferase assay using endogenous miR-125b-1 expressing normal hOMK107 cell and the luciferase activity was increased by antisense miR-125b (Figure 5c lower part), suggesting that miR-125b-1 could bind to the 3 0 -UTR of TACSTD2. In addition, we immunoprecipitated Argonaute 2 (AGO2), a core component of RNA-induced silencing complex (RISC), and demonstrated the direct binding of miR-125b-1 to endogenous TACSTD2 mRNA (Figure 5d ). Taken together, these findings indicate that TACSTD2 is a target of miR-125b-1.
miR-125b-1 impairs clonogenicity and invasiveness of HNSCC cells Increased invasion and proliferation is a characteristic of aggressive cancer cells. To determine whether the effect of miR-125b-1 and TACSTD2 could result in increased cell phenotype changes, we performed cell invasion and colony-formation assays. 
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2.0E-04 miR-125b-1 inhibits activation of the MAPK pathway through modulation of TACSTD2 expression Next we focused on identification of signal pathways that may be affected by miR-125b-1 because a recent report shows that murine Tacstd2 increases the level of phosphorylated ERK1/2. 20 We determined that phosphorylation of ERK and the downstream effector, MYC, were significantly decreased in FaDu cells stably expressing short-hairpin RNA for TACSTD2 (sh-TACSTD2); miR-125-1 overexpression also led to reduced levels of phospho-ERK (p-ERK) and MYC ( Figure 6d ). These reduced MAPK pathways were rescued by overexpression of TACSTD2 in LV-miR-125b-1-FaDu cells (Figure 6e ) or by suppression of miR125b in keratinocyte hOMK107 (Figure 6f ).
An inhibitor of ERK phosphorylation, U0126, reduces cell proliferation of HNSCC cells To ascertain the biochemical effect of inhibition of ERK phosphorylation, we examined the effect of U0126, an inhibitor of ERK phosphorylation 21 by colony-formation assay. Colony formation was inhibited by suppression of TACSTD2 and MYC using shorthairpin RNAs, and the suppression has enhanced by U0126 (Figure 7a upper part) . Moreover, U0126 suppressed colonyformation ability by transfection with TACSTD2 and MYC in FaDu-LV-miR-125b-1 cells (Figure 7a lower part) . ERK and the downstream effector, MYC with effect of U0126, effect of transfection of shTACSTD2, shMYC, TACSTD2 and MYC were determined by western blot in FaDu or FaDu-LV-miR-125b-1 cells (Figures 7b-d) . The results showed inhibition of cell proliferation by U0126 and demonstrated that HNSCC cell proliferation depended on expression of TACSTD2 and ERK phosphorylation. Inverse correlation of expression of miR-125b and miR-125b target genes Many targets of miR-125b have been reported, but their evaluation in HNSCC had not been reported. In this study, we assessed expression of the reported targets of miR-125b in HNSCC-derived cells. We found that the levels of TACSTD2 and MYC expression were downregulated by shTACSTD2 and miR-125b-1 (Figure 8a ), and these reductions were confirmed at the mRNA and protein expression levels ( Figure 6d ). TACSTD2 and MYC expression correlated inversely with miR-125b expression level and was high in HNSCC cell line samples compared with normal tissues or normal keratinocytes, while ERBB2, 3, BAK1 and TP53 expression were not (Figure 8b ).
DISCUSSION
miRNA dysregulation has been found in all human cancers. 4 Although aberrant expression of miR-489, miR-21, miR-205, miR-204 and miR-125b has been observed in head and neck cancers by miRNA profiling studies, [22] [23] [24] [25] [26] their functional involvement in cancer pathogenesis and progression had not been assessed. We focused on functional studies of miR-125b and showed that miR125b-1 has a tumor-suppressive role in HNSCC. This result was validated by the inhibition of tumorigenesis after overexpression of miR-125b-1 in HNSCC cells by invasion and clonogenicity analyses.
Decrease of miR-125b expression relative to normal cell controls is the one of the most commonly reported miRNA changes in a variety of cancers, and there are several reports of the possible targets of this miRNA.
27-31 miR-125b-1 and miR-125b-2, which are precursors of miR-125b, are located on chromosome 11q24.1 and 21q21.1, respectively, regions involved in loss of heterozygosity in oral, lung, breast and ovarian cancer. [32] [33] [34] [35] However, the mechanism of regulation of miR-125b-1, 2 expressions had not been defined, because the mature sequences of the two miRNAs are identical, and microarray and qPCR methods used did not allow discrimination between miR-125b-1 and miR-125b-2. Recent studies have shown that miRNAs can also be dysregulated by promoter methylation in human malignancies. 36, 37 In this study, we carried out deletion analysis and examined the methylation status of miR-125b-1, 2 to clarify the regulation of this miRNA in HNSCC. We found that none of the genomic regions that included miR-125b-1 and miR-125b-2 were deleted. On the other hand, we found that the promoter of miR-125b-1 but not of miR-125b-2 was hypermethylated in all HNSCC-derived cells we tested and that the methylation status of miR-125b-1 was inversely correlated with the expression of miR-125b-1 precursor RNA. These data suggested that miR-125b-1 is downregulated by methylation.
Using bioinformatics tools and database searches, 41000 candidate targets of miR-125b were identified. We analyzed expression of some of them and selected for study TACSTD2 gene and the protein, with known alterations of expression in epithelial cancer, including HNSCC. [13] [14] [15] [16] [17] Our study, using luciferase assay and AGO2 containing RISC immunoprecipitation (IP), showed that the TACSTD2 gene is directly targeted by miR-125b-1. TACSTD2 is highly expressed in several types of cancers [13] [14] [15] [16] [17] and expression of TACSTD2 has been correlated with increased metastatic disease and decreased overall survival. 13, 15, 17 We showed that knocking down TACSTD2 expression by short-hairpin RNA in HNSCC cells resulted in a 50-70% inhibition of colony formation in anchoragedependent and -independent assays and 450% inhibition in the cell invasion assay. Thus, our results suggest that TACSTD2 may be a key player in HNSCC by functioning as an oncogene. A very recent report suggests that murine Tacstd2 expression increases the level of phosphorylated ERK, suggesting its possible involvement in murine pancreatic cancer. 20 The functional role of TACSTD2 in cancer is not well understood and its physiological ligand is still unknown. By contrast, activation of the MAPK pathway by membrane protein and cell-surface receptor is well known. 27, 38 Our study demonstrated that miR125b-1 suppressed MAPK by regulating the targeted TACSTD2 and the suppressed MAPK pathway recovered with re-overexpression of TACSTD2. To investigate the clinical relevance of the MAPK pathway, we tested 2.0E-04 miR-125b-1 regulates TACSTD2 and MAPK pathway H Nakanishi et al the effects of this pathway inhibition using U0126 as an ERK phosphorylation inhibitor. U0126 is a highly potent inhibitor of ERK1/2 (IC50 ¼ 0.1-20 mM), a protein kinase with important roles in cell proliferation. 21 In response to treatment with U0126, cell proliferation was decreased in parallel with inhibition of phosphorylation of ERK.
TP53 and BAK1 were also reported as targets of miR-125b in prostate cancer and neuroblastoma cells, consistently with the oncogenic function of miR-125b. 30, 39 These reports contradict tumor-suppressor function of miR-125b, and the role of miR-125b in malignancy has been somewhat controversial. In our study, the assessment of the expression levels of miR-125b-1 and of several reported targets of miR-125b, ERBB2, ERBB3, BAK1 and TP53 did not show inverse correlation in HNSCCs. On the other hand, mRNA expression levels of TACSTD2 and MYC clearly showed inverse correlation. MYC is known to be a downstream target of phospho-ERK. 40 Our investigation is the first to show that miR-125b-1 directly regulates TACSTD2 expression and contributes to MAPK pathway activation in HNSCC (Figure 9 ). This pathway could be targeted by drugs, providing novel opportunities for rational treatment of HNSCC.
MATERIALS AND METHODS
Cell lines and tissue samples
Human squamous carcinoma-derived cell lines, including pharyngeal cancers (FaDu, Detroit562) and oral cancers (Cal 27, SCC4, SCC9, SCC15, SCC25), were obtained from ATCC (Manassas, VA, USA). SCC4, SCC9, SCC15 and SCC25 cell lines were maintained in DMEM (Dulbecco's modified eagle's medium) plus Ham's 12 (1:1) medium supplemented with 10% fetal calf serum. Detroit 562, FaDu and CAL 27 cell lines were cultured as monolayers in DMEM, supplemented with 10% fetal bovine serum, 0.075% sodium bicarbonate, 0.6 mg/ml l-glutamine and kept at 37 1C in humidified atmosphere with 5% CO 2 in air. Human primary keratinocytes from normal oral mucosa (hOMK102, hOMK107, hOMK109) were obtained from Cell Research Corporation (International Plaza, Singapore) and maintained in Epilife basal medium with 1% epilife-defined growth supplement and 1% antibiotics and used between passages 4 and 8. Human normal tissue, tongue and pharynx were obtained from BioChain (Newark, CA, USA). Human papillomavirus testing was performed in all HNSCC cell lines, primary keratinocytes and normal tissues evaluating by PCR using miRNA microarrays-based miRNA expression profiling assay and data analysis Total RNA from cell lines and tissues was isolated by TRIzol (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Microarray analysis was performed as described. 38 Briefly, 5 mg of total RNA was used for hybridization on miRNA microarray chips. These chips contain genespecific 40-mer oligonucleotide probes, spotted and covalently attached to a polymeric matrix. The microarrays were hybridized in 6 Â SSPE (0.9 M NaCl, 60 mM NaH 2 PO 4 Á H 2 O, 8 mM EDTA, pH 7.4)/30% formamide at 25 1C for 18 h, washed in 0.75 Â TNT (Tris-HCl/NaCl/Tween 20) at 37 1C for 40 min and processed by using a method of direct detection of the biotincontaining transcripts by streptavidin-Alexa Fluor 647 conjugate. Processed slides were scanned by using a microarray scanner, with the laser set to 635 nm, at fixed photomultiplier tube (PMT) setting, and a scan resolution of 10 mm.
Bisulfite conversion of genomic DNA and methylation-specific PCR Bisulfite conversion of genomic DNA was performed as described in the EZ DNA methylation kit (Zymo Research, Irvine, CA, USA) to create a template for methylation-specific PCR. For bisulfite sequencing, the sodium bisulfitemodified DNA was subjected to PCR with primers for miR-125b-1 (Gene ID: 406911) designed to amplify nucleotides from 922 to 1073 relative to the transcription start point and primers for miR-125b-2 (Gene ID: 262205364) designed to amplify nucleotides from 1598 to 1790 relative to the transcription start point.
5-aza-CdR treatment for demethylating
Normal human keratinocytes hOMK102, 107 and SCC cell lines FaDu, SCC4 were seeded 1 Â 106 per well in six-well plates and cultured with 10 mmol/l 5-aza-CdR (Sigma-Aldrich, St Louis, MO, USA) for 5 days. The medium containing agent was replaced every 24 h. RNA was isolated and quantitative reverse transcriptase-PCR (qRT-PCR) was carried out to evaluate the restoration of miR-125b expression after 5-aza-CdR treatment. miR-125b-1 regulates TACSTD2 and MAPK pathway H Nakanishi et al qPCR and end-point PCR for detection of mature, precursor or genome of miR-125b and candidate genes
To detect mature miR-125b expression, we used Trizol reagent to isolate total RNA, which was then amplified by TaqMan stem-loop RT-PCR method. 23 TaqMan miRNA assays used the Human Panel-Early Access Kit (ABI, Forest City, CA, USA), which includes 10 human cells as well as 3 negative controls. We also used individual miR-125b-specific primer sets and TaqMan probe from ABI to detect miR-125b expression in patient specimens and cell lines. In all, 5 mg of total RNA was subjected to cDNA synthesis by using SuperScript III First-Strand Synthesis System (Invitrogen) for detection of miR-125b1, 2 precursor and mir-125b downstream gene. At the end of the reaction, 40 ml of TE (10 mM Tris, 1 mM EDTA, pH7.6) was added and 1 ml of the reaction (1/60 volume) was used as a template for PCR. TACSTD2 or candidate target genes transcripts and miR-125b1, 2 precursor were quantified by using QuantiTect SYBR Green RT-PCR kit (QIAGEN, Valencia, CA, USA) and iCycler real-time PCR detection system (Bio-Rad, Hercules, CA, USA) for the detection of PCR product. Primer sequences are shown in Supplementary Table S1 . Cycle threshold (Ct) value of the tested cDNA was converted to weight according to the standard curve. For detection of loss of genomic region of miR-125b-1, 2, genomic DNA was extracted and quantified by using Quantitect SYBR RT-PCR kit and iCycler real-time PCR detection system (Bio-Rad).
Construction for reporter assay
A reporter plasmid was constructed by cloning into pGL3 control vector (Promega, Madison, WI, USA), a 200-bp genomic sequence corresponding to part of the 3 0 -UTR region (TACSTD2 #1), using PCR primers, 5 0 -TG CTCTAGAGATTTCGGTATCGTCCCAGA-3 0 and 5 0 -TGCTCTAGAGGACCGAAAG GGGATACATT-3 0 . The PCR product was then digested with XbaI and cloned into the reporter plasmid pGL3 control (Promega) downstream of the luciferase gene. As the negative control, mutations into the miR-125b-binding site of the TACSTD2 3 0 -UTR were introduced using mutant assay for GeneTailor (Invitrogen). The primers used for the miR-binding site mutagenesis are as follows and mutation sequences are indicated by noncapitalized letters: TACSTD2-mutF 5 0 -TTAATAGATCCTGGCggttcacTCTCCT TTCTT-3 0 and TACSTD2-mutR 5 0 -GCCAGGATCTATTAAACCTGGTGTG-3 0 . All plasmid constructs were confirmed by DNA sequencing.
Luciferase target assay HEK-293T and hOMK107 cells were counted, 4 Â 105 cells seeded in 12-well plates and co-transfected using Lipofectamine 2000 (Invitrogen) with 2 mg of TACSTD2#1/pGL3-control vector and miR-125b with 2 mg of pRL-TK vector (Promega, San Luis Obispo, CA, USA). At 24 h after transfection, the cells were lysed in 500 ml of a passive lysis buffer. Cell lysates were directly miR-125b-1 regulates TACSTD2 and MAPK pathway H Nakanishi et al
RNA interference
Short hairpins (Santa Cruz Biotech, Dallas, TX, USA) targeting human TACSTD2 and MYC were cloned into the lentiviral vector. Lentivirus was generated as previously described. 20 Infected cells were selected in puromycin to generate pooled stable knockdown populations.
Western blot analysis
Whole-cell lysates were prepared from FaDu and SCC9 cells 16 h after transfection or each condition and subjected to western blot analysis. Proteins were subjected to SDS-PAGE and transferred to PVDF membrane. After treatment with blocking reagent (PIERCE, Rockford, IL, USA), the membrane was incubated with goat polyclonal antiserum against TACSTD2 (R&D, Minneapolis, MN, USA), rabbit polyclonal antisera against ERK1/2, phospho-ERK1/2 (Thr202/Tyr204) and MYC obtained from Cell Signaling (Danvers, MA, USA).
Cell invasion assay
Effect of miR-125b on the invasion ability of SCC9 and FaDu cells was determined using QCM 96-well Cell Invasion Assay kit (Chemicon, Temecula, CA, USA). Cells infected with either miR-125b or control lentiviral vectors were seeded into inserts at 2 Â 10 4 per insert in serumfree medium and then transferred to wells filled with culture medium containing 10% fetal bovine serum. The plates with cells were incubated for 16 h at 37 1C in a CO 2 incubator. After incubation, non-invading cells on the top of the membrane were removed by scraping. Migrating cells on the bottom of the insert were incubated with 150 ml of prewarmed cell detachment buffer for 30 min, dissociated from the membrane and detected by CyQuant GR dye. The fluorescence plate was read using a 480/520 nm filter set.
Soft agar colony-formation assay agar (0.6%; bottom agar) was added to six-well plates and allowed to solidify. Cells (1 Â 10 5 ) were resuspended in 1 ml of 0.3% agar (top agar) and overlayed onto the bottom agar. Cells were fed with top agar every 3 days, and after 4 weeks, colonies in agar were solubilized and measured by fluorescence plate reader.
Cell colony-forming assay FaDu cells infected with miR-125b, shTACSTD2, shMYC or control lentiviral vectors or transfected with TACSTD2, MYC or control vectors were seeded at 1 Â 10 3 per 3 ml medium in six-well plates. Two weeks later, colonies were counted using the QuantityOne software (Bio-Rad). The mean±s.d. of three independent experiments performed in triplicate was reported.
U0126 treatment for ERK inhibition
Cells for various experimental conditions were plated and U0126 (Cell Signaling Technology) was added into the culture medium at a concentration of 1 mM. For a single treatment, three identical plates were treated and cultured for 24 h.
Statistical analysis
The mean±s.d. was calculated for each data point. Differences between groups were analyzed by the Student's t-test or analysis of variance (Dunnett's multiple comparison test). A P-value o0.05 was considered statistically significant.
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